Weight loss drugs could soon be used to treat these seven other health conditions
However, Novo Nordisk has warned that the rise in copycat versions of its weight-loss drug in the U.S. and competition from Lilly across several markets is expected to hurt Wegovy sales this year.
Both companies are actively exploring other medical uses for these GLP-1 drugs, aiming to broaden their market reach and secure wider health insurance coverage, a strategy that has already seen some success.
Here are some of the other conditions the drugs are being used and tested for:
Alcohol addiction
A study conducted by the University of Copenhagen's Psychiatric Centre Rigshospitalet, is investigating whether semaglutide - the main ingredient in Wegovy and Ozempic - can help reduce alcohol intake in 108 patients diagnosed with alcohol use disorder and obesity.
Alzheimer's disease
Novo Nordisk is testing semaglutide in a late-stage trial in patients with early Alzheimer's disease.
The study, which will enrol 1,840 patients, could have an initial data readout as early as later this year.
Cardiovascular disease
Eli Lilly was testing tirzepatide - the main ingredient in Mounjaro and Zepbound - for patients with heart failure and obesity. Lilly had said it would enrol about 700 people in the study, but the company said in May that it had withdrawn its U.S. application for heart failure approval.
The European Medicines Agency backed the use of Novo's semaglutide to help ease heart failure symptoms in people with obesity in September 2024.
Chronic kidney disease
Novo's Ozempic is approved in the United States for reducing the risk of kidney failure and disease progression, as well as the risk of death due to heart problems in diabetes patients with chronic kidney disease.
Lilly's tirzepatide is being evaluated in a mid-stage study of patients with chronic kidney disease and obesity. Lilly plans to enrol up to 140 participants with the study expected to be completed next year.
Liver disease
Novo is testing semaglutide in a late-stage trial of patients with a common, but difficult to treat, type of fatty liver disease called non-alcoholic steatohepatitis, or NASH. The study is expected to be completed in April 2029 and include about 1,200 patients.
Lilly's tirzepatide helped up to 74 per cent of patients achieve absence of the disease with no worsening of liver scarring at 52 weeks, compared with 13 per cent of patients on placebo, in a mid-stage trial for NASH, which is also now referred to as metabolic dysfunction-associated steatohepatitis, or MASH.
Neurological disorders
Researchers at the Danish Headache Centre are testing semaglutide along with a very low-calorie diet as a treatment for new-onset idiopathic intracranial hypertension, a condition associated with obesity in which blood pressure inside the head rises.
The study has enrolled about 50 patients and is expected to be completed in October 2025.
Sleep apnea
Zepbound was approved by the U.S. Food and Drug Administration for obstructive sleep apnea in December 2024, making it the first drug to directly treat patients with the common disorder that causes breathing disruption while sleeping.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
2 hours ago
- Washington Post
The worst way to achieve herd immunity is demonizing anti-vaxxers
Monica Hesse described in her July 15 op-ed, 'There's no vaccine for this,' her dismay at the state of U.S. measles vaccination rates. She fears that the loss of herd immunity will harm those who aren't able to be vaccinated, but wrote that 'what makes me worry most is that the people causing the collapse in herd immunity do not seem to understand that.' That framing reveals an unfortunately common lack of understanding of those 'causing the collapse.'
Yahoo
3 hours ago
- Yahoo
The disease which takes 3.5 years to diagnose after symptoms start
A disease that affects almost one million people in the UK takes around 3.5 years to diagnose, researchers have found. Dementia sufferers have to wait a lengthy time from the onset of symptoms to an official diagnosis. And some people with early-onset dementia have an even longer wait of just over four years. A new study by UCL researchers is the first systematic review and meta-analysis of global evidence examining time to diagnosis in dementia. READ MORE: Learner drivers 'struggling to pass' as three Midland test centres among the UK's toughest The researchers reviewed data from 13 previously published studies which took place in Europe, US, Australia and China, reporting data on 30,257 participants. The study, published in the International Journal of Geriatric Psychiatry, investigated the average interval between symptom onset rated by patients or family carers using interviews or medical records to the final diagnosis of dementia. Lead author, Dr Vasiliki Orgeta, said: "Timely diagnosis of dementia remains a major global challenge, shaped by a complex set of factors, and specific healthcare strategies are urgently needed to improve it. "Other studies estimate that only 50-65% of cases are ever diagnosed in high-income countries, with many countries having even lower diagnostic rates. 'Timely diagnosis can improve access to treatments and for some people prolong the time living with mild dementia before symptoms worsen.' In a pooled meta-analysis of 10 of the included studies, the researchers found that it typically takes 3.5 years from the first alert of symptoms to a patient receiving a diagnosis of dementia, or 4.1 years for those with early-onset dementia, with some groups more likely to experience longer delays, a spokesperson for UCL said. They found that younger age at onset and having frontotemporal dementia were both linked to longer time to diagnosis. While data on racial disparities was limited, one of the studies reviewed found that black patients tended to experience a longer delay before diagnosis. Dr Orgeta said: 'Our work highlights the need for a clear conceptual framework on time to diagnosis in dementia, developed in collaboration with people with dementia, their carers, and supporters.' Dr Phuong Leung (UCL Division of Psychiatry) said: 'Symptoms of dementia are often mistaken for normal ageing, while fear, stigma, and low public awareness can discourage people from seeking help.' Professor Rafael Del-Pino-Casado, of the University of Jaén, Spain, said: 'Within healthcare systems, inconsistent referral pathways, limited access to specialists, and under-resourced memory clinics can create further delays. For some, language differences or a lack of culturally appropriate assessment tools can make access to timely diagnosis even harder.' Dr Orgeta added: 'To speed up dementia diagnosis, we need action on multiple fronts. Public awareness campaigns can help improve understanding of early symptoms and reduce stigma, encouraging people to seek help sooner. "Clinician training is critical to improve early recognition and referral, along with access to early intervention and individualised support so that people with dementia and their families can get the help they need.' The NHS lists common early symptoms of dementia as: memory loss difficulty concentrating finding it hard to carry out familiar daily tasks, such as getting confused over the correct change when shopping struggling to follow a conversation or find the right word being confused about time and place mood changes
Yahoo
3 hours ago
- Yahoo
Zamalek Appoints Villarreal Doctor Gerard Manzanet to Lead Medical Staff
Spanish sports medicine expert to head Zamalek's medical team as part of international revamp Zamalek Appoints Villarreal Doctor Gerard Manzanet to Lead Medical Staff Zamalek SC've officially named Spanish doctor Gerard Manzanet as the new head of the club's medical department, the board announced on Sunday. Advertisement The decision was made by sporting director John Edward in coordination with the club board, led by Hussein Labib as part of broader strategy to boost the team's medical structure with world class expertise. Top Level La Liga Experience Dr. Manzanet's renowned name in Spanish football having served as first team doctor at Villarreal CF since November 2021 and brings with him extensive experience from La Liga. He holds a Master's degree in Sports Medicine from TECH University, a FIFA /CIES diploma in football medicine and specialized credentials in sports emergency care, orthopedic injuries and musculoskeletal MRI from Francisco de Vitoria University in Spain. He's also WADA certified.
